http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-453932-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f07293d4b34d8372fb0775181fef9d23
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D317-58
classificationIPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D317-50
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-275
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-33
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-495
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D317-58
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-35
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-135
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D241-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D295-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D241-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D295-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D405-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D405-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D407-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D-
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K-
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-235
filingDate 1976-12-03^^<http://www.w3.org/2001/XMLSchema#date>
publicationDate 1977-11-01^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber ES-453932-A1
titleOfInvention PROCEDURE FOR THE PREPARATION OF NEW 1-PHENYL-PROPYL (2) -PIPERAZINES RACEMIC OR OPTICALLY ACTIVE.
abstract Novel substituted N-[1-(3,4-methylenedioxyphenyl)-propyl-(2)]-N'-phenylpiperazines of the formula I shown, wherein either R1 and R2 denote chlorine or R1 denotes methyl and R2 denotes methoxy, are prepared by treating an appropriately substituted halogenopropane, especially an appropriately substituted chloropropane, with catalytically activated hydrogen. Advantageously, the process is carried out in the presence of an acid-binding agent and at an elevated temperature. The compounds of the formula I may be obtained in the form of the racemates or of the optically active antipodes. The products of the process show a good central-depressant action as well as an excellent blood lipid level-lowering and cholesterol-lowering action.
priorityDate 1974-09-03^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458393787
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458392451
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID414939035
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID313
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419530545
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID10899
http://rdf.ncbi.nlm.nih.gov/pubchem/anatomy/ANATOMYID178
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458393636
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419559516
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID7096

Showing number of triples: 1 to 42 of 42.